AUSTIN, Texas and KOLN, Germany, June 8, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and the Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene today announced that Luminex's newly released xTAG® Gastrointestinal Pathogen Panel (GPP) is being used successfully as a first-line screen for patients at Kliniken der Stadt Koln suspected of having an E. coli infection. This includes the detection of hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain responsible for the current outbreak.
Kliniken der Stadt Koln Institut fur Pathologie worked with Luminex last week to quickly implement this new diagnostic assay when they successfully showed xTAG GPP was able to accurately detect the outbreak pathogens in patient samples.
As of 7 June at 15:00 CET World Health Organization (WHO) reported 2,745 people in 12 European countries have been sickened by E. coli. Since the beginning of May, there have been 722 notified cases of HUS and 25 deaths – nineteen fatalities resulting from HUS infections and six fatalities from E. coli non-HUS infections. Staff at Kliniken der Stadt Koln Institut fur Pathologie, who use the Luminex xTAG Respiratory Viral Panel (RVP), have quickly adopted xTAG GPP as an important first line screen to help manage the current outbreak in Germany.
Since xTAG GPP can rapidly and simultaneously identify 95% of acute gastroenteritis pathogens, infected patients can be quickly identified and appropriately managed. Positive STEC patients can be closely monitored and treated in parallel with confirmatory testing. Additionally, patients who are infected with other causative infectious agents; or those who are negative, can be quickly identified and receive appropriate care or be discharged, thus making healthcare resources available to those most in need.
"Prior to the approval last month of xTAG GPP, we did not have a test that would allow us to rapidly detect a comprehensive array of disease-causing pathogens for infectious gastroenteritis," said PD Dr. Frauke Mattner, of Kliniken der Stadt, Institute of Pathology and Institute for Hygiene. "The ability of xTAG GPP to detect not only several different types of E. coli, but also the presence of the Stx-2 gene, a key marker of this more severe STEC strain, is allowing rapid identification of patients who may be suffering from an infection of this outbreak strain. This innovative technology is an important advance and an invaluable tool in the management of the current crisis."
"We are pleased and proud that our new innovative assay, xTAG GPP, is helping health care professionals in Germany rapidly identify patients who may be infected with this pathogen and is assisting them during this crisis," said Patrick J. Balthrop, president and CEO of Luminex. "All of my Luminex colleagues across the globe share a serious concern for those affected and hope for a resolution to the current situation as quickly as possible."
About xTAG Gastrointestinal Pathogen Panel (GPP)
Luminex's xTAG GPP can simultaneously detect fifteen of the most common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as E. coli, Campylobacter, Salmonella and C. difficile all within 5 hours. xTAG GPP received CE mark approval in May of 2011 from European regulatory authorities and is now being used as an important aid for patient triage in the current outbreak.
More information on Luminex and xTAG GPP can be found at www.luminexcorp.com/gpp , or Luminex's European office at, Krombraak 15, 4906 CR Oosterhout, The Netherlands, +220.127.116.1133.
About Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene
Kliniken der Stadt Koln gGmbH is a network of urban hospitals that includes the hospitals in Cologne-Merheim and Cologne-Holweide as well as the Amsterdamer StraBe pediatric hospital. With more than 1,500 beds, the hospital group is the largest provider of inpatient health services in Cologne. Approximately 4,000 staff members treat, care for and handle about 60,000 patients per year on an inpatient basis, and more than twice as many on an outpatient basis. With annual revenues of roughly 280 million euros, the network is one of the large urban hospitals in Germany. Kliniken der Stadt Koln gGmbH is run by CEO Prof. Christian Schmidt, MD and MPH, and Roman Lovenfosse-Gehrt. Research teaching is a top priority at Kliniken der Stadt Koln gGmbH: the three urban hospitals are teaching hospitals of the University of Cologne; the hospital at Cologne-Merheim is a clinical center of the University of Witten/Herdecke. http://www.kliniken-koeln.de/uberuns/Hygiene/
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The company's xMAP multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including genomic and proteomic research markets. The company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at http://www.luminexcorp.com/.
Porter Novelli - EU
+32 (0)2 35 01 67
PD Dr. Oliver
Kliniken der Stadt Koln
Ostmerheimer Strasse 200,
51109 Koln, Cologne, Germany
PD Dr. Frauke Mattner
Kliniken der Stadt Koln
Ostmerheimer Strasse 200
51109 Koln, Cologne, Germany
|SOURCE Luminex; Kliniken der Stadt Köln, Institute of Pathology and Institute for Hygiene|
Copyright©2010 PR Newswire.
All rights reserved